Pfizer
At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products. Our global portfolio includes medicines and vaccines as well as many of the world's best-known consumer health care products. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 150 years, Pfizer has worked to make a difference for all who rely on us.
Business & Industry
- Red Cross and Novo Nordisk announce ground-breaking partnership to tackle chronic care in humanitarian crises
- FDA grants Breakthrough Therapy Designation for Roche's Hemlibra in haemophilia A without inhibitors
- Novartis renews commitment to malaria elimination, investing USD 100 million to research and develop next-generation antimalarials
- Boehringer Ingelheim and Lilly announce an academic collaboration with University of Oxford
- Bristol-Myers Squibb announces worldwide collaboration with Janssen to develop and commercialize next-generation cardiovascular therapy
Research & Development
- Music intensifies effects of anti-hypertensive medication
- Diabetes drug may not reduce risk of death
- Personalized tumor vaccine shows promise in pilot trial
- New class of drugs could help tackle treatment-resistant cancers
- New immunotherapy for lung cancer shows promise of success
- Human drug trials are compromised by poor reporting of animal research
- 'Coffee filter' helps make new cancer drug Z-endoxifen 1,000 times cheaper
Conferences & Events
- SMi presents the 2nd annual conference on Pharmaceutical Microbiology West Coast
- Introducing SMi's 6th annual conference on Pharmaceutical Freeze Drying Technology this June 2018
- Adaptive Designs in Clinical Trials Conference 2018
- Drug Safety 2018
- Controlled Release Delivery Conference 2018
- Superbugs & Superdrugs Conference 2018
- Highly Potent Active Pharmaceutical Ingredients (HPAPI) Conference 2018
Regulatory Affairs
- FDA approves first therapy for rare inherited form of rickets, x-linked hypophosphatemia
- FDA permits marketing of artificial intelligence-based device to detect certain diabetes-related eye problems
- FDA approves new treatment for certain digestive tract cancers
- FDA approves first treatment for breast cancer with a certain inherited genetic mutation
- FDA updates the label of Tasigna to reflect that certain patients with a type of leukemia may be eligible to stop treatment after sustained response
- FDA approves novel gene therapy to treat patients with a rare form of inherited vision loss
- FDA launches new tool for sharing information that allows doctors to better manage antibiotic use; improve patient care